REG - Cizzle Biotechnology - Conversion of Convertible Loan Notes

Cizzle Biotechnology HoldingsAnnouncement

06/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260506:nRSF1272Da&default-theme=true

RNS Number : 1272D  Cizzle Biotechnology Holdings PLC  06 May 2026

6 May 2026

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Conversion of Convertible Loan Notes

Cizzle Biotechnology, the UK based diagnostics developer of early cancer
tests, announces that the Company has received a notice to convert £400,000
of convertible loan notes ("CLNs") held by Frazer Lang (registered in the name
of Ropemaker Nominees Limited) (the "Note Holder"), an existing investor in
the Company.

On 20 May 2025, the Company secured funding of £150,000 through the issue of
CLNs to Frazer Lang and the funding provided by him was extended though the
issue of further CLNs of £250,000 on 5 November 2025.  The CLNs are
convertible at the election of the Note Holder into new ordinary shares of
0.01p in the Company ("Ordinary Shares") at a price of 1.4 pence per Ordinary
Share.  Following receipt of the conversion notice the Company will therefore
issue 28,571,429 new Ordinary Shares ("Conversion Shares") to the Note Holder.

In addition, the Company announced on 2 April 2026 that it has entered into a
new facility to provide the Company with up to £250,000 through the potential
issue of further unsecured convertible loan notes ("Facility Notes") to the
Note Holder. The Facility Notes can be drawn down, at the sole election of the
Company as to £100,000 on 1 May 2026, £100,000 on 1 June and £50,000 on 1
July 2026. The Facility Notes are convertible at 1.4 pence per Ordinary Share
at any time up to 30 October 2026. The Company has now drawn down £100,000 of
the Facility Notes and following completion of the £400,000 CLN conversion,
the Note Holder will hold £100,000 of CLNs.

Admission and Total Voting Rights

Application will be made for the 28,571,429 Conversion Shares to be admitted
to trading on the Main Market of the London Stock Exchange and to listing on
the FCA Official List ("Admission"). It is expected that the issue of the
28,571,429 Conversion Shares will take place, Admission will become effective
and that dealings in the Conversion Shares on the Main Market of the London
Stock Exchange will commence on or around 11 May 2026.

On Admission, the Company will have 424,963,202 Ordinary Shares in issue, each
with one voting right. There are no shares held in treasury. Therefore, the
Company's total number of Ordinary Shares and voting rights will be
424,963,202  and this figure may be used by shareholders from Admission as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                    +44(0) 20 3328 5656
 John Depasquale (Corporate Finance)
 Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited  +44(0) 20 3934 6632
 Tim Metcalfe
 Florence Staton

 

About Cizzle Biotechnology

 

The CIZ1B biomarker is a naturally occurring variant of the cell nuclear
protein CIZ1, which is linked with the preservation of epigenetic integrity.
 CIZ1B is highly associated with the presence of early-stage lung cancer and
can be measured in small quantities of blood.  The Company has developed
CIZ1B into a non-invasive, cost-effective blood test to help in the early
detection of lung cancer and has now entered commercial royalty-bearing
arrangements to license its proprietary technology, and into collaborations
with centres of excellence in cancer care.  Cizzle was admitted to the
Standard segment of the main market of the London Stock Exchange in May
2021.

 

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

 

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBRGDUIXGDGLU



            Copyright 2019 Regulatory News Service, all rights reserved